SLC10A4 regulates IgE-mediated mast cell degranulation in vitro and mast cell-mediated reactions in vivo

Pettersson, Hanna; Zarnegar, Behdad; Westin, Annika; Persson, Viktor; Peuckert, Christiane; Jönsson, Jan‐Ingvar; Hallgren, Jenny; Kullander, Klas

doi:10.1038/s41598-017-01121-8

Cited by 11 publications

(5 citation statements)

References 51 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCA is commonly used immediate allergic response model, which is characterized by increased vascular permeability. Evans blue, a dye that binds with extravasated plasma albumin, is injected to visualize and quantify the increased permeability characteristic of PCA ( Pettersson et al, 2017 ). Thus, EL-mediated reduction in pigmentation and ear swelling that are observed in the PCA model is suggested to arise from the suppression of allergic responses.…”

Section: Discussionmentioning

confidence: 99%

Elaeocarpusin Inhibits Mast Cell-Mediated Allergic Inflammation

Kim

Choi

et al. 2018

Front. Pharmacol.

View full text Add to dashboard Cite

Mast cells are major effector cells for allergic responses that act by releasing inflammatory mediators, such as histamine and pro-inflammatory cytokines. Accordingly, different strategies have been pursued to develop anti-allergic and anti-inflammatory candidates by regulating the function of mast cells. The purpose of this study was to determine the effectiveness of elaeocarpusin (EL) on mast cell-mediated allergic inflammation. We isolated EL from Elaeocarpus sylvestris L. (Elaeocarpaceae), which is known to possess anti-inflammatory properties. For this study, various sources of mast cells and mouse anaphylaxis models were used. EL suppressed the induction of markers for mast cell degranulation, such as histamine and β-hexosaminidase, by reducing intracellular calcium levels. Expression of pro-inflammatory cytokines, such as tumor necrosis factor-α and IL-4, was significantly decreased in activated mast cells by EL. This inhibitory effect was related to inhibition of the phosphorylation of Fyn, Lyn, Syk, and Akt, and the nuclear translocation of nuclear factor-κB. To confirm the effect of EL in vivo, immunoglobulin E-mediated passive cutaneous anaphylaxis (PCA) and ovalbumin-induced active systemic anaphylaxis (ASA) models were induced. EL reduced the PCA reaction in a dose dependent manner. In addition, EL attenuated ASA reactions such as hypothemia, histamine release, and IgE production. Our results suggest that EL is a potential therapeutic candidate for allergic inflammatory diseases that acts via the inhibition of mast cell degranulation and expression of proinflammatory cytokines.

show abstract

Section: Discussionmentioning

confidence: 99%

Elaeocarpusin Inhibits Mast Cell-Mediated Allergic Inflammation

Kim

Choi

et al. 2018

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Release of ATP-laden vesicles is dependent on the PI3K/Rho/ROCK pathways and on the reorganization of the actin cytoskeleton and, of relevance in tumors, is promoted by hypoxia [ 31 , 32 ]. Release of ATP by stimulated exocytosis occurs in various cell types, including neurons and secretory cells [ 33 , 34 ]. Anecdotal evidence suggests that T lymphocytes may also release ATP by a similar mechanism; thus, vesicular release could be important in setting ATP levels in the TME during T lymphocytes activation [ 35 ].…”

Section: Mechanisms Of Atp Releasementioning

confidence: 99%

Extracellular ATP: A Feasible Target for Cancer Therapy

Vultaggio-Poma

Sarti

Virgilio

2020

Cells

163

216

View full text Add to dashboard Cite

Adenosine triphosphate (ATP) is one of the main biochemical components of the tumor microenvironment (TME), where it can promote tumor progression or tumor suppression depending on its concentration and on the specific ecto-nucleotidases and receptors expressed by immune and cancer cells. ATP can be released from cells via both specific and nonspecific pathways. A non-regulated release occurs from dying and damaged cells, whereas active release involves exocytotic granules, plasma membrane-derived microvesicles, specific ATP-binding cassette (ABC) transporters and membrane channels (connexin hemichannels, pannexin 1 (PANX1), calcium homeostasis modulator 1 (CALHM1), volume-regulated anion channels (VRACs) and maxi-anion channels (MACs)). Extracellular ATP acts at P2 purinergic receptors, among which P2X7R is a key mediator of the final ATP-dependent biological effects. Over the years, P2 receptor- or ecto-nucleotidase-targeting for cancer therapy has been proposed and actively investigated, while comparatively fewer studies have explored the suitability of TME ATP as a target. In this review, we briefly summarize the available evidence suggesting that TME ATP has a central role in determining tumor fate and is, therefore, a suitable target for cancer therapy.

show abstract

“…The allergenic protein and IgE interact in serum and surface-bound IgE via high-affinity IgE receptors FcɛRI on the surface of mast cells (Amin, 2012;Youssef, Schuyler, Wilson, & Oliver, 2010). Mast cell degranulation releases mediators such as histamine, prostaglandin (PGs), leukotrienes (LTs), platelets activation factor, and cytokines (IL-4, IL-5, and IL-13), which cause allergenic inflammation and adverse health reactions (da Silva, Jamur, & Oliver, 2014;Paul & Zhu, 2010;Pettersson et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Peanut Allergy: Characteristics and Approaches for Mitigation

Shah

Shi

Ashley

et al. 2019

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

Peanut allergy has garnered significant attention because of the high sensitization rate, increase in allergy, and severity of the reaction. Sufficiently reliable therapies and efficient mitigating techniques to combat peanut allergy are still lacking. Current management relies on avoiding peanuts and nuts and seeds with homologous proteins, although adverse events mostly occur with accidental ingestion. There is a need for hypoallergenic peanut products to protect sensitized individuals and perhaps serve as immunotherapeutic products. Alongside traditional practices of thermal and chemical treatment, novel processing approaches such as high‐pressure processing, pulsed ultraviolet light, high‐intensity ultrasound, irradiation, and pulsed electric field have been performed toward reducing the immunoreactivity of peanut. Covalent and noncovalent chemical modifications to proteins also have the tendency to alter peanut allergenicity. Enzymatic hydrolysis seems to be the most advantageous technique in diminishing the allergenic potential of peanut. Furthermore, the combined processing approach (hurdle technologies) such as enzymatic hydrolysis followed by, or in conjunction with, roasting, high pressure and heat, ultrasound with enzymatic treatment, or germination have shown a significant reduction of peanut immunoreactivity and may emerge as useful techniques in reducing the allergenicity of peanut and other foods. This study represents our current knowledge about the alterations in allergenic properties of peanut via different processing mechanisms as well as evaluating its future potential, geographical based data on increasing sensitization, clinical relevance, eliciting dose, and current management of peanut allergy. Furthermore, the molecular characteristics and clinical relevance of peanut allergens have been discussed.

show abstract

SLC10A4 regulates IgE-mediated mast cell degranulation in vitro and mast cell-mediated reactions in vivo

Cited by 11 publications

References 51 publications

Elaeocarpusin Inhibits Mast Cell-Mediated Allergic Inflammation

Elaeocarpusin Inhibits Mast Cell-Mediated Allergic Inflammation

Extracellular ATP: A Feasible Target for Cancer Therapy

Peanut Allergy: Characteristics and Approaches for Mitigation

Contact Info

Product

Resources

About